A Multicenter Open-label Clinical Study on the Prevention of Premature Ovarian Failure After HSCT

HSCT is an effective method to cure hematologic malignancies. However, the reproductive system is prone to be damaged during radiotherapy and chemotherapy before transplantation, leading to ovarian failure, followed by infertility and premature ovarian failure (POF), which seriously affect the long-term quality of life of patients. This clinical trial aimed to observe the effect of Gonadotropin-releasing hormone analogues (GnRHa) on ovarian function in women of reproductive age after HSCT, so as to provide clinical evidence for whether GnRHa should be used for the prevention of POF.

Inclusion Criteria:Diagnosed with acute leukemia, MDS, lymphoma, multiple myeloma, SAA and other hematological diseases, with the indications for autologous or allogeneic hematopoietic stem cell transplantation.Female, aged 18-45 years.Ovarian function was normal before treatment.Volunteer to participate in clinical research and sign the informed consent form.Exclusion Criteria:No menstruation before treatment, undergone hysterectomy or ovarian surgery.Abnormal sexual development.Received radiotherapy.Combined with tumors affecting gonadal function.Deep vein thrombosis.Hypertension, liver and/or kidney dysfunction cannot tolerate hematopoietic stem cell transplantation.